About Stereotaxis (OTCMKTS:STXS)
Stereotaxis, Inc. is a United States-based healthcare technology company. The Company is engaged in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease. The Company also provides information management solutions for the interventional lab. The Stereotaxis platform helps physicians to provide patient care with robotic precision and enhanced integration of procedural information. The Company's Epoch solution includes the Niobe ES remote magnetic navigation system, the Odyssey portfolio of lab optimization, networking and patient information management systems, and the Vdrive robotic navigation system and consumables. The Niobe ES remote magnetic navigation system includes the Navigant software user interface and the QuikCAS catheter advancement system. The Vdrive robotic navigation system with Niobe ES magnetic navigation system provides navigation and stability for diagnostic and ablation devices.
Industry, Sector and Symbol
Industry MED PRODS
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$31.14 million
Price / Sales0.50
Price / CashN/A
Book Value($0.98) per share
Price / Book-0.70
Return on Equity-5.60%
Return on Assets7.09%
Stereotaxis (OTCMKTS:STXS) Frequently Asked Questions
What is Stereotaxis' stock symbol?
Stereotaxis trades on the OTCMKTS under the ticker symbol "STXS."
How were Stereotaxis' earnings last quarter?
Stereotaxis Inc (OTCMKTS:STXS) announced its earnings results on Tuesday, March, 6th. The medical equipment provider reported ($0.01) EPS for the quarter. The medical equipment provider earned $7.56 million during the quarter. Stereotaxis had a negative net margin of 18.90% and a negative return on equity of 5.60%. View Stereotaxis' Earnings History.
When will Stereotaxis make its next earnings announcement?
Who are some of Stereotaxis' key competitors?
Some companies that are related to Stereotaxis include Cesca Therapeutics (KOOL), Microbot Medical (MBOT), InVivo Therapeutics (NVIV), Dynatronics (DYNT), Valeritas (VLRX), Cellectar Biosciences (CLRB), Check Cap (CHEK), Neovasc Inc (US) (NVCN), Neurometrix (NURO), SenesTech (SNES), Sunshine Heart (CHFS), Amedica (AMDA), TearLab (TEAR), Lombard Medical Technologies (EVARF), Avinger (AVGR), Imaging Canada Liquidating (IMRSQ) and Echo Therapeutics (ECTE).
Who are Stereotaxis' key executives?
Stereotaxis' management team includes the folowing people:
- David Fischel, Chairman of the Board, Acting Chief Executive Officer (Age 30)
- Martin C. Stammer, Chief Financial Officer (Age 36)
- Karen W. Duros, Senior Vice President, General Counsel, Secretary (Age 62)
- David A. Giffin, Vice President - Human Resources (Age 68)
- Paul A. Brathwaite Ph.D., Vice President - Research & Development (Age 47)
- Joseph E. Kiani, Director (Age 52)
- Arun Swarup Menawat Ph.D., Director (Age 62)
- David W. Benfer, Independent Director (Age 70)
- Nathan Fischel M.D., Independent Director (Age 61)
- Robert J. Messey, Independent Director (Age 71)
Has Stereotaxis been receiving favorable news coverage?
Media stories about STXS stock have trended positive on Tuesday, according to Accern. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stereotaxis earned a daily sentiment score of 0.28 on Accern's scale. They also gave media coverage about the medical equipment provider an impact score of 46.63 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Stereotaxis' major shareholders?
How do I buy shares of Stereotaxis?
Shares of STXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stereotaxis' stock price today?
One share of STXS stock can currently be purchased for approximately $0.69.
How big of a company is Stereotaxis?
Stereotaxis has a market capitalization of $16.17 million and generates $31.14 million in revenue each year. The medical equipment provider earns $-5,890,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Stereotaxis employs 120 workers across the globe.
How can I contact Stereotaxis?
Stereotaxis' mailing address is 4320 Forest Park Avenue Suite 100, ST.LOUIS MO, 63108. The medical equipment provider can be reached via phone at 314-678-6100 or via email at [email protected]
MarketBeat Community Rating for Stereotaxis (STXS)MarketBeat's community ratings are surveys of what our community members think about Stereotaxis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Stereotaxis (OTCMKTS:STXS) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Stereotaxis (OTCMKTS:STXS) Earnings History and Estimates Chart
Stereotaxis (OTCMKTS STXS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/14/2018|| || || || || || || || |
|3/6/2018||Q4 2017||($0.01)||$7.56 million||View||Listen|
|11/9/2017||Q3 2017||($0.02)||$8.14 million||View||N/A|
|8/10/2017||Q2 2017||($0.02)||$8.47 million||View||N/A|
|5/8/2017||Q1 2017||$0.01||$6.98 million||View||Listen|
|3/16/2017||Q4 2016||$0.24||$7.31 million||View||N/A|
|11/7/2016||Q3 2016||($0.09)||$8.33 million||View||N/A|
|8/9/2016||Q2 2016||($0.11)||$7.88 million||View||N/A|
|5/9/2016||Q1||($0.11)||$9.50 million||$8.60 million||View||Listen|
|2/22/2016||Q4||($0.10)||$9.80 million||$9.20 million||View||Listen|
|11/3/2015||Q3||($0.05)||$8.90 million||$9.30 million||View||Listen|
|8/4/2015||Q215||($0.12)||$120.60 million||$9.66 million||View||N/A|
|5/6/2015||Q115||($0.15)||$8.40 million||$9.50 million||View||Listen|
|2/25/2015||Q414||$0.04||$9.10 million||$9.80 million||View||Listen|
|11/5/2014||Q3 2014||($0.10)||$8.85 million||View||N/A|
|8/4/2014||Q2 2014||($0.16)||$8.05 million||View||N/A|
|5/6/2014||Q1||($0.16)||$8.40 million||$8.40 million||View||Listen|
|2/25/2014||Q4||($0.19)||$12.20 million||$9.10 million||View||Listen|
|11/12/2013||Q3||($0.26)||$9.70 million||$10.80 million||View||N/A|
|8/8/2013||Q2 2013||($0.59)||($0.37)||$10.80 million||$9.70 million||View||Listen|
|5/13/2013||Q1 2013||($0.50)||($0.61)||$12.00 million||$8.40 million||View||Listen|
|11/5/2012||Q312||($0.72)||($0.33)||$10.30 million||$11.60 million||View||N/A|
Stereotaxis (OTCMKTS:STXS) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Stereotaxis (OTCMKTS:STXS)
No dividend announcements for this company have been tracked by MarketBeat.com
Stereotaxis (OTCMKTS STXS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 22.05%
Institutional Ownership Percentage: 6.07%
Stereotaxis (OTCMKTS STXS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/15/2015||Fred A Middleton||Director||Sell||26,064||$1.57||$40,920.48|| |
|6/12/2015||Fred A Middleton||Director||Sell||16,273||$1.61||$26,199.53|| |
|6/9/2015||Fred A Middleton||Director||Sell||106,876||$1.65||$176,345.40|| |
|3/13/2015||David Benfer||Director||Buy||3,000||$1.95||$5,850.00|| |
|12/12/2014||William C Mills III||CEO||Buy||10,000||$1.45||$14,500.00|| |
|12/9/2014||Fred A Middleton||Director||Sell||8,551||$1.51||$12,912.01|| |
|12/5/2014||William C Mills III||CEO||Buy||10,000||$1.43||$14,300.00|| |
|12/3/2014||Fred A Middleton||Director||Sell||15,809||$1.59||$25,136.31|| |
|8/11/2014||William C Mills III||CEO||Buy||10,000||$2.75||$27,500.00|| |
|3/13/2014||Fred A Middleton||Director||Sell||24,302||$4.21||$102,311.42|| |
|8/23/2013||Fred A Middleton||Director||Sell||14,600||$3.67||$53,582.00|| |
|8/20/2013||Christopher D Alafi||Major Shareholder||Sell||261,241||$3.74||$977,041.34|| |
|8/7/2013||Fred A Middleton||Director||Sell||78,974||$10.13||$800,006.62|| |
|11/30/2012||Fred A Middleton||Director||Buy||24,360||$1.53||$37,270.80|| |
Stereotaxis (OTCMKTS STXS) News Headlines
Stereotaxis (OTCMKTS:STXS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Stereotaxis (OTCMKTS:STXS) Income Statement, Balance Sheet and Cash Flow Statement
Stereotaxis (OTCMKTS STXS) Stock Chart for Tuesday, March, 20, 2018